Sign in

CIK 0001636282

  • Large accelerated filer

Spyre Therapeutics, Inc.

Sign in to watch
Ticker
SYRE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464312787
Phone
+1 617-651-5940
Business address
221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
Former names
Aeglea BioTherapeutics, Inc.
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Planned sale Director sold 80,000 shares at an average $74.40 ($5,952,050)
  6. 4 Planned sale Chief Financial Officer sold 12,500 shares at $71.37 ($892,125)
  7. 4 Planned sale Chief Medical Officer sold 78,333 shares at an average $71.50 ($5,600,701)
  8. 4 Planned sale Chief Executive Officer sold 15,000 shares at an average $71.37 ($1,070,507)
  9. 4 Planned sale Chief Executive Officer sold 15,000 shares at an average $49.33 ($739,912)
  10. 4 Planned sale Chief Medical Officer sold 7,958 shares at $50.00 ($397,900)
  11. 4 Planned sale Chief Financial Officer sold 7,500 shares at an average $49.34 ($370,076)
  12. 4 Planned sale Chief Financial Officer sold 2,500 shares at an average $40.65 ($101,620)
  13. 4 Planned sale Chief Executive Officer sold 15,000 shares at an average $42.19 ($632,866)
  14. 4 Planned sale Chief Executive Officer sold 15,000 shares at an average $32.80 ($492,045)
  15. 4 Other acquisition Director acquired 63,227 shares (other)
  16. 4 Derivatives Options or other derivatives
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Planned sale Chief Executive Officer sold 15,000 shares at an average $30.68 ($460,134)

Page 2 of 14 · 271 filings